

## Ervogastat, DGAT2 inhibitor

| Catalog      | Unit  |
|--------------|-------|
| TBI4459-5MG  | 5 mg  |
| TBI4459-25MG | 25 mg |

### Product Details

**Formal Name:** 2-[5-[(3-Ethoxy-2-pyridinyl)oxy]-3-pyridinyl]-N-[(3S)-oxolan-3-yl]pyrimidine-5-carboxamide

**Alternate Names:** PF-06865571

**Molecular Formula:** C<sub>21</sub>H<sub>21</sub>N<sub>5</sub>O<sub>4</sub>

**Formula Weight:** 407.4

**CAS Number:** 2186700-33-2


**Purity:** >98%

**Formulation:** Powder

**Solubility:** Soluble in DMSO (up to at least 25 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 2 years.



### Applications

DGAT2 inhibitor

### Functions

Potent (IC<sub>50</sub> = 17.2 nM) and selective (against DGAT1 and MGATs 1-3) inhibitor of diacylglycerol transferase 2 (DGAT2). It reduced liver and plasma triglyceride levels in Sprague-Dawley rats fed a high fat high cholesterol diet by 49% and 70% respectively. Ervogastat displayed efficacy in combination with the ACC inhibitor clesacostat in resolving metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.

### Application Procedures

First dissolved in DMSO (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 3 months.

**For research use only.**